Michael D. Miller

4.4k total citations
62 papers, 3.1k citations indexed

About

Michael D. Miller is a scholar working on Virology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Michael D. Miller has authored 62 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Virology, 20 papers in Epidemiology and 19 papers in Infectious Diseases. Recurrent topics in Michael D. Miller's work include HIV Research and Treatment (24 papers), Hepatitis C virus research (14 papers) and Hepatitis B Virus Studies (11 papers). Michael D. Miller is often cited by papers focused on HIV Research and Treatment (24 papers), Hepatitis C virus research (14 papers) and Hepatitis B Virus Studies (11 papers). Michael D. Miller collaborates with scholars based in United States, France and Italy. Michael D. Miller's co-authors include Norman L. Letvin, Shelly Xiong, Huiling Yang, William E. Delaney, Carol I. Lord, Yasuhiro Yasutomi, Craig S. Gibbs, Keith A. Reimann, David I. Watkins and Gail P. Mazzara and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Michael D. Miller

59 papers receiving 3.0k citations

Peers

Michael D. Miller
William L. Heyward United States
Philip Cunningham Australia
Christophe Pasquier France
Francesco Mazzotta Italy
Laurent Bélec France
J F Peutherer United Kingdom
Hugo Soudeyns Canada
Ralph DeMasi United States
Édouard Tuaillon France
Indira Hewlett United States
William L. Heyward United States
Michael D. Miller
Citations per year, relative to Michael D. Miller Michael D. Miller (= 1×) peers William L. Heyward

Countries citing papers authored by Michael D. Miller

Since Specialization
Citations

This map shows the geographic impact of Michael D. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael D. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael D. Miller more than expected).

Fields of papers citing papers by Michael D. Miller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael D. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael D. Miller. The network helps show where Michael D. Miller may publish in the future.

Co-authorship network of co-authors of Michael D. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Michael D. Miller. A scholar is included among the top collaborators of Michael D. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael D. Miller. Michael D. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Haller, R. De, Michael D. Miller, Iris Kufferath, et al.. (2024). Immune evasion by proteolytic shedding of natural killer group 2, member D ligands in Helicobacter pylori infection. Frontiers in Immunology. 15. 1282680–1282680. 11 indexed citations
2.
Spak, Cedric W., Medhat Askar, Aaron Killian, et al.. (2021). ALVR109, an off-the-shelf partially HLA matched SARS-CoV-2–specific T cell therapy, to treat refractory severe COVID-19 pneumonia in a heart transplant patient: Case report. American Journal of Transplantation. 22(4). 1261–1265. 18 indexed citations
3.
Lim, So‐Yon, Christa E. Osuna, Peter Hraber, et al.. (2018). TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy. Science Translational Medicine. 10(439). 116 indexed citations
4.
Camus, Grégory, Simin Xu, Bin Han, et al.. (2017). Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems. Virology. 514. 134–141. 11 indexed citations
5.
Ku, Karin S., Ramakrishna K. Chodavarapu, Ross Martin, et al.. (2016). Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6. Journal of Clinical Microbiology. 54(7). 1835–1841. 7 indexed citations
6.
Bennett, David M., et al.. (2016). Predicting Vancouver Types B1 and B2 Periprosthetic Fractures of the Femur. UNM’s Digital Repository (University of New Mexico). 5(1). 20. 1 indexed citations
7.
Liu, Yang, Michael D. Miller, & Kathryn M. Kitrinos. (2016). Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro. Antiviral Research. 139. 25–31. 24 indexed citations
8.
Rajyaguru, Sonal, Huiling Yang, Ross Martin, Michael D. Miller, & Hongmei Mo. (2013). Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates. Antiviral Research. 100(2). 328–336. 1 indexed citations
9.
Wong, Kelly A., Simin Xu, Ross Martin, Michael D. Miller, & Hongmei Mo. (2012). Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a. Virology. 429(1). 57–62. 13 indexed citations
10.
Klatt, Nichole R., Emi Shudo, Jessica C. Engram, et al.. (2010). CD8+ Lymphocytes Control Viral Replication in SIVmac239-Infected Rhesus Macaques without Decreasing the Lifespan of Productively Infected Cells. PLoS Pathogens. 6(1). e1000747–e1000747. 128 indexed citations
11.
Bianchi, Elisabetta, Paolo Ingallinella, Marco Finotto, et al.. (2009). Synthetic Peptide Vaccines: The Quest to Develop Peptide Vaccines for Influenza, HIV and Alzheimer's Disease. Advances in experimental medicine and biology. 611. 121–123. 2 indexed citations
12.
Su, Bin, Renee Hrin, Barrett R. Harvey, et al.. (2007). Automated high-throughput purification of antibody fragments to facilitate evaluation in functional and kinetic based assays. Journal of Immunological Methods. 322(1-2). 94–103. 10 indexed citations
13.
Luftig, Micah A., Marco Mattu, Paolo Di Giovine, et al.. (2006). Structural basis for HIV-1 neutralization by a gp41 fusion intermediate–directed antibody. Nature Structural & Molecular Biology. 13(8). 740–747. 105 indexed citations
14.
Carruth, Lucy M., M. Christine Zink, Patrick M. Tarwater, et al.. (2005). SIV‐specific T lymphocyte responses in PBMC and lymphoid tissues of SIV‐infected pigtailed macaques during suppressive combination antiretroviral therapy. Journal of Medical Primatology. 34(3). 109–121. 13 indexed citations
15.
McGaughey, Georgia B., Gaetano Barbato, Elisabetta Bianchi, et al.. (2004). Progress Towards the Development of a HIV-1 gp41-Directed Vaccine. Current HIV Research. 2(2). 193–204. 42 indexed citations
16.
17.
Schwartz, Stephanie A., Mihra S. Taljanovic, John T. Ruth, & Michael D. Miller. (2003). Bilateral asymmetric hip dislocation: case report and literature review. Emergency Radiology. 10(2). 105–108. 11 indexed citations
18.
Letvin, Norman L., Michael D. Miller, Ling Shen, Zheng W. Chen, & Yasuhiro Yasutomi. (1993). Simian immunodeficiency virus-specific cytotoxic T lymphocytes in rhesus monkeys: characterization and vaccine induction. Seminars in Immunology. 5(3). 215–223. 7 indexed citations
19.
Ringler, D J, et al.. (1992). Simian immunodeficiency virus-specific cytotoxic T lymphocytes are present in the AIDS-associated skin rash in rhesus monkeys. The Journal of Immunology. 149(2). 728–734. 23 indexed citations
20.
Miller, Michael D., Hiroshi Yamamoto, A. Hughes, David I. Watkins, & Norman L. Letvin. (1991). Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. The Journal of Immunology. 147(1). 320–329. 143 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William L. Heyward Breakdown of academic impact, for papers by Philip Cunningham Breakdown of academic impact, for papers by Christophe Pasquier Breakdown of academic impact, for papers by Francesco Mazzotta Breakdown of academic impact, for papers by Laurent Bélec Breakdown of academic impact, for papers by J F Peutherer Breakdown of academic impact, for papers by Hugo Soudeyns Breakdown of academic impact, for papers by Ralph DeMasi Breakdown of academic impact, for papers by Édouard Tuaillon Breakdown of academic impact, for papers by Indira Hewlett
Rankless by CCL
2026